Corient Private Wealth LP Trims Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Corient Private Wealth reduced its Thermo Fisher Scientific stake by 15% in the second quarter, selling 124,657 shares and retaining 707,412 shares valued at approximately $354.7 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in earnings per share and $11.99 billion in revenue, with revenue increasing 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $624.64.
• The company declared a quarterly dividend of $0.47 per share, equivalent to an annualized $1.88 payout and a 0.3% yield. Insiders sold 73,768 shares worth $44.1 million over the past three months, including sales by the CEO and an executive vice president.

Corient Private Wealth LP cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 707,412 shares of the medical research company's stock after selling 124,657 shares during the period. Corient Private Wealth LP owned approximately 0.19% of Thermo Fisher Scientific worth $354,690,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth about $170,000. Raymond James Financial Inc. increased its stake in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company's stock worth $315,781,000 after buying an additional 53,542 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company's stock valued at $244,099,000 after buying an additional 2,262 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $603.80 on Friday. The company has a market cap of $223.26 billion, a PE ratio of 32.48, a P/E/G ratio of 2.53 and a beta of 0.85. The firm's 50 day moving average price is $578.63 and its 200-day moving average price is $517.89. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Insider Buying and Selling

In related news, CEO Marc Casper sold 275 shares of the firm's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Shafer sold 25,500 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company's stock, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock worth $44,122,820 in the last three months. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TMO shares. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Deutsche Bank Aktiengesellschaft lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Wednesday. Scotiabank assumed coverage on Thermo Fisher Scientific in a report on Wednesday. They set an "outperform" rating on the stock. BMO Capital Markets lowered Thermo Fisher Scientific to a "market perform" rating in a research report on Wednesday. Finally, Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $624.64.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.